CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells (CSCs), congratulates Robert Weinberg, Ph.D., Verastem co-founder and co-chair of the Scientific Advisory Board, and announces the presentation of preclinical data at the American Association for Cancer Research annual meeting being held March 31 to April 4, 2012, in Chicago, IL.
